EMMA-RUTH PAZ-QUERUBIN: Open Payments
NPI 1790015659 · VOORHEES, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,399 in 120 payments from 42 companies in 2025. Trend: 2023 $1,375 · 2024 $2,504 · 2025 $2,399
Food & beverage: $2,299Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $301 |
| SOBI, INC | 5 | $168 |
| Daiichi Sankyo Inc. | 7 | $155 |
| AstraZeneca Pharmaceuticals LP | 6 | $105 |
| Gilead Sciences, Inc. | 6 | $104 |
| Genmab U.S., Inc. | 5 | $100 |
| Merck Sharp & Dohme LLC | 5 | $99 |
| ADC THERAPEUTICS AMERICA, INC. | 4 | $97 |
| ARRAY BIOPHARMA INC | 4 | $84 |
| Genentech USA, Inc. | 4 | $74 |
Products named: Doptelet, KISQALI, Trodelvy, ENHERTU, ZYNLONTA, REBLOZYL, PLUVICTO, Tivdak.
Industry payments across NJ — which companies pay providers there.
